Drug Approved to Prevent Graft-vs-Host Disease

The FDA has approved the first drug to prevent acute graft-vs-host disease (GVHD) when used with immunosuppressant therapy for patients aged 2 years or older who are undergoing hematopoietic stem cell transplantation.

Leave a Reply